Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS)‘s stock had its “buy” rating reaffirmed by stock analysts at Ascendiant Capital Markets in a research report issued on Wednesday,Benzinga reports. They presently have a $6.60 price target on the stock. Ascendiant Capital Markets’ price target points to a potential upside of 123.73% from the company’s previous close.

Separately, Alliance Global Partners decreased their price objective on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a research report on Tuesday.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $2.95 on Wednesday. The firm’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $2.52. The stock has a market cap of $14.28 million, a price-to-earnings ratio of -0.52 and a beta of 7.71. Vivos Therapeutics has a twelve month low of $1.91 and a twelve month high of $48.79.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.